| Description: |
TNO155 is a first-in-class, selective, orally active wild-type SHP2 metamorphosis inhibitor with an IC50 value of 0.011 µM. tNO155 has good water solubility (0.736 mM), moderate lipophilicity (LogP=1.6), high lipophilic efficiency (>6), and no hERG inhibition (IC50 >30 μM) and no phototoxicity. Does not inhibit CYP450. |
| Stability and Solubility Advice: |
Information concerning product stability, particularly in solution, has rarely been reported and in most cases we can only offer a general guide.
We recommend that stock solutions, once prepared, are stored aliquoted in tightly sealed vials and used within 1 month. Avoid repeated freeze and thaw cycles. Storage conditions for some special products should refer to their storage details. |
